Moxduo Must Show Clear Benefit Over Opioid Components, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency hands QRxPharma its third “complete response” letter in less than two years for the fixed-dose combination of immediate-release morphine and oxycodone. New CEO says the company will develop a clinical program to clearly demonstrate Moxduo's benefit.
You may also be interested in...
FDA “Combination Rule” Trips Up QRxPharma’s Moxduo
Morphine/oxycodone fixed-dose product must offer efficacy or safety advantage over individual drug components because the two opioids are not generally used together to treat acute pain, agency says; QRxPharma fails to convince advisory committee that respiratory safety advantage exists.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.